PAVM - Lucid Diagnostics inks strategic partnership with UpScriptHealth

PAVmed ([[PAVM]] -1.0%) company Lucid Diagnostics has entered into a definitive agreement with UpScriptHealth related to the company's EsoGuard test.UpScriptHealth to provide telemedicine services to evaluate consumers with chronic heartburn seeking early esophageal precancer detection using Lucid’s EsoGuard test.Lucid believes its EsoGuard and EsoCheck are capable of serving as a widespread screening tool to prevent esophageal cancer deaths, through the early detection of esophageal precancer in at-risk GERD patients.

For further details see:

Lucid Diagnostics inks strategic partnership with UpScriptHealth